Actinium Pharmaceuticals Inc (STU:7AY1)
€ 1.321 -0.001 (-0.08%) Market Cap: 41.72 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 1.15 GF Score: 27/100

Actinium Pharmaceuticals Inc at Guggenheim Healthcare Talks: Radiopharmaceuticals Day Transcript

May 15, 2023 / 07:20PM GMT
Release Date Price: €7.5
Charles Zhu
Guggenheim Securities - Analyst

All right, let's get our next session started. Once again, I'm Charles Zhu, Senior Biotech Analyst here at Guggenheim Securities. Joining us for our next session will be Actinium Pharmaceuticals. Thank you Sandesh as well as Madhuri for joining us here today. Perhaps just to get us started off, would you like to run through and introduce your company, your platform, and pipeline?

Sandesh Seth
Actinium Pharmaceuticals, Inc. - CEO & Chairman

Sure. Absolutely. Thanks, Charles. So we are a public company, so a little SEC disclaimer there. Why don't we just skip through this slide, please?

All right. So look, we are at a radio conference and we do have a radiopharmaceutical technology. But the case I'm going to make for many of you is for us, the real story is about what we could do with the clinical data that this company has generated and has made public in the last four or five months. And on that basis, I would argue for us that come to work at Actinium. We are an AML story and that we have one of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot